Trial Profile
Safety and efficacy of the first-generation paclitaxel-eluting stents, the first-generation everolimus-eluting stent versus the second-generation everolimus- or zotarolimus-eluting stents in patients with de novo coronary bifurcation lesions
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Apr 2017
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Paclitaxel (Primary) ; Sirolimus (Primary) ; Zotarolimus (Primary)
- Indications Coronary artery disease
- Focus Adverse reactions; Therapeutic Use
- 03 Apr 2017 New trial record